Research progress of synthetic lactacystin and its analogs as β-lactone proteasome inhibitors

doi:10.5246/jcps.2017.07.052

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (7): 467-478.DOI: 10.5246/jcps.2017.07.052

• Reviews • Next Articles

Research progress of synthetic lactacystin and its analogs as β-lactone proteasome inhibitors

Yuping Wang, Xiaowei Zhu, Jian Xin, Yanyan Guo, Xiangnan Xu, Yuheng Ma^*

School of Pharmacy, Inner Mongolia Medical University, Hohhot 010110, China

Received:2017-03-27 Revised:2017-03-29 Online:2017-07-28 Published:2017-05-29
Contact: Tel.: +86-471-6653149, E-mail: myhstar@126.com
About author:In 2009, Dr. Ma obtained his Ph.D. degree in medicinal chemistry from School of Pharmaceutical Sciences, Peking University. During 2009–2012, he did postdoctoral research at college of engineering and college of chemistry and molecular engineering, Peking University. In October 2012, he joined the School of Pharmacy at Inner Mongolia Medicinal University as an Associate Professor. His research interest is discovery de novo antitumor drug.
Supported by:
National Natural Science Foundation of China (Grant No. 21362021). Inner Mongolia Natural Science Foundation (Grant No. 2015MS0206).

Abstract

Abstract:

As Bortezomib and Carfilzomib are approved to treat refractory multiple myeloma, 20S proteasome has become a highly interested tumor therapeutic target. Because of drug resistance of Bortezomib and Carfilzomib, β-lactone natural products are used to treat cancer, arthritis, asthma, and Alzheimer’s diseases. Now the second generation drug candidates are developed, eg. Salinosporamide A (1). This review is aiming to encapsulate the synthetic methods of β-lactone proteasome inhibitors, lactacystin (3) and its analogs.

Key words: Lactacystin, β-Lactone, Proteasome, Inhibitors

CLC Number:

R916

Supporting:

Yuping Wang, Xiaowei Zhu, Jian Xin, Yanyan Guo, Xiangnan Xu, Yuheng Ma. Research progress of synthetic lactacystin and its analogs as β-lactone proteasome inhibitors[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(7): 467-478.

References

[1] Yao, S.Y.; Zhou, Y. J. Chin. Pharm. Sci. 2016, 25, 408-418.

[2] Chen, Y.X.; Yuan, X.; Ge, Z.M.; Ran, F.X.; Wu, J.; Li, R.T.; Cui, J.R. J. Chin. Pharm. Sci. 2014, 23, 601-609.

[3] Tompa, P. Chem. Soc. Rev. 2016, 45, 4252-4284.

[4] Li, Y.J.; Xu, F.R.; Niu, Y.; Zou, X.M.; Yuan, Y.; Gao, H.F.; Wang, C.; Yang, G.Y.; Sun, Q.; Xu, P. J. Chin. Pharm. Sci. 2011, 20, 564-571.

[5] Gopinath, P.; Ohayon, S.; Nawatha, M.; Brik, A. Chem. Soc. Rev. 2016, 45, 4171-4198.

[6] Ma, Y.H.; Qu, L.L.; Liu, Z.M.; Zhang, L.R.; Yang, Z.J.; Zhang, L.H. Curr. Med. Chem. 2011, 11, 2906-2922.

[7] Kong, D.Y.; Li, M.N.; Wang, R.; Zi, G.F.; Hou, G.H. Org. Biomol. Chem. 2016, 14, 1216-1220.

[8] Donohoe, T.J.; Pullin, R.D.C. Chem. Comm. 2012, 48, 11924-11938.

[9] Hager, A.; Vrielink, N.; Hager, D.; Lefranc, J.; Trauner, D. Nat. Prod. Rep. 2016, 33, 491-522.

[10] Muroi, M.; Futamura, Y.S.; Osada, H. Nat. Prod. Rep. 2016, 33, 621-625.

[11] Grawert, M.A.; Groll, M. Chem. Commun. 2012, 48, 1364-1378.

[12] Corey, E.J.; Reichard, G.A. J. Am. Chem. Soc. 1992, 114, 10677-10678.

[13] Xie, J.H.; Zhou, Q.L. Acc. Chem. Res. 2008, 41, 581-593.

[14] Ding, K.L.; Han, Z.B.; Wang, Z. Chem. Asian. J. 2009, 4, 32-41.

[15] Xie, J.H.; Zhou, Q.L. Acta. Chim. Sin. 2014, 72, 778-797.

[16] Corey, E.J.; Li, W.D.Z. Chem. Pharm. Bull. 1999, 47, 110-113.

[17] Sunazuka, T.; Nagamitsu, T.; Matsuzaki, K.; Tanaka, H.; Omura, S.; Smith, A.B. J. Am. Chem. Soc. 1993, 115, 5032-5304.

[18] Gill, K.A.; Berrue, F.; Arens, J.C.; Carr, J.; Kerr, R.G. J. Nat. Prod. 2015, 78, 822-826.

[19] Meijere, A.D.; Korotkov, V.S.; Lygn, A.V.; Larionvo, O.V.; Sokolov, V.V.; Graef, T. Org Biomol Chem. 2012, 10, 6363-6374.

[20] Pattenden, G.; Rescourio, G. Org. Biomol. Chem. 2008, 6, 3428-3438.

[21] Corey, E.J.; Li, W.D.; Nagamitsu, T. Angew. Chem. Int. Ed. 1998, 37, 1676-1679.

[22] Corey, E.J.; Choi, S. Tetrahedron Lett. 1993, 34, 6969-6972.

[23] Riant, O.; Hannedouche, J. Org. Biomol. Chem. 2007, 5, 873-888.

[24] Hayes, C.J.; Sherlock, A.E.; Selby, M.D. Org. Biomol. Chem. 2006, 4, 193-195.

[25] Akbalina, Z.F.; Zlotslii, S.S.; Kabal’nova, N.N.; Shereshovets, V.V. Russ. J. Appl. Chem. 2002, 75, 1120-1122.

[26] Corey, E.J.; Li,W.D.; Reichard, G.A. J. Am. Chem. Soc. 1998, 120, 2330-2336.

[27] Wardrop, D.J.; Bowen, E.G. Chem. Comm. 2005, 5106-5108.

[28] Mehta, V.P.; Punji, B. RSC. Adv. 2013, 3, 11957-11986.

[29] Taber, D.F.; Meagley, R.P.; Doren, D.J. J. Org. Chem. 1996, 61, 5723-5728.

[30] Stang, P.J. Chem. Rev. 1978, 78, 383-405.

[31] Stang, P.J. Angew. Chem. Int. Ed. 1992, 31, 274-285.

[32] Helmchen, G. Tetrahedron Lett. 1995, 1127-1148.

[33] Kirmse, W.G. Angew. Chem. Int. Ed. 1997, 36, 1164-1170.

[34] Sunazuka, T.; Nagamitsu, T.; Tanaka, H. J. Am. Chem. Soc. 1996, 118, 3584-3590.

[35] Szostak, M.; Spain, M.; Procter, D.J. Chem. Soc. Rev. 2013, 42, 9155-9183.

[36] Sasaki, M.; Tanino, K.; Hirai, A. Org. Lett. 2003, 5, 1789-1791.

[37] Green, M.P.; Prodger, J.C.; Hayes, C.J. Tetrahedron Lett. 2002, 43, 2649-2652.

[38] Dupau, P.; Epple, R.; Thomas, A.A.; Fokin, V.V.; Sharpless, K.B. Adv. Synth. Catal. 2002, 344, 421-433.

[39] Corey, E.J.; Li, W.D.; Nagamitsu, T. Angew. Chem. Int. Ed. 1998, 37, 1676-1679.

[40] Chida, N.; Takeoka, J.; Tsutsumi, N.; Ogawa, S. J. Chem. Soc. Chem. Comm. 1995, 793-794.

[41] Fenteany, G.; Standaert, R.F.; Reichard, G.A.; Schreiber, S.L. Proc. Natl. Acad. Sci. USA. 1994, 91, 3358-3362.

[42] Grawert, M.A.; Groll, M. Chem. Comm. 2012, 48, 1364-1378.

[43] Hager, A.; Vrielink, N.; Hager, D.; Lefranc, J.; Trauner, D. Nat. Prod. Rep. 2016, 33, 491-522.

[44] Jones, G.R.; Landais, Y. Tetrahedron. 1996, 52, 7599-7662.

[45] Donohoe, T.J.; Sintim, H.O.; Sisangia, L. Angew. Chem. Int. Ed. 2004, 116, 2343-2346.

[46] Shibasaki, M.; Kanai, M. Org. Biomol. Chem. 2007, 5, 2027-2039.

[47] Aubry, S.; Sasaki, K.; Eloy, L.; Aubert, G.; Retailleau, P.; Cresteil, T.; Crich, D. Org. Biomol. Chem. 2011, 9, 7134-7143.

[48] Gill, K.A.; Berrue, F.; Arens, J.C.; Carr, G.; Kerr, R.G. J. Nat. Prod. 2015, 78, 822-826.

[49] Meijere, A.D.; Korotkov, V.S.; Lygin, A.V.; Larionov, O.V.; Sokolov, V.V.; Graef, T. Org. Biomol. Chem. 2012, 10, 6363-6374.

[50] Tello, R.; Hallada, L.; Niroula, D. Org. Biomol. Chem. 2015, 13, 10127-10130.

Research progress of synthetic lactacystin and its analogs as β-lactone proteasome inhibitors

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xiaowei Chi, Qi Li, Yi Zhong, Tong Gong, Chuxiao Yi, Liangren Zhang, Zhenming Liu. Discovery of potential xanthine oxidase inhibitors based on virtual screening [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 626-635.
[2]	Yuxia Zhu, Lingjian Zhang, Yiming Hu, Weihua Liu, Liping Guan, Lin Lin. Study on synthesis of naringenin derivatives and cholinesterase inhibitory activity in marine Chinese medicine [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 636-644.
[3]	Chonghao Wu, Panjie Huang, Chunqi Yang, Chuan Gao, Ming Zeng. The efficacy and safety of immune checkpoint inhibitors in malignant pleural mesothelioma: A systematic review [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 291-301.
[4]	Ying Fu, Simo Liu, Yan Ma, Nannan Wu. Canagliflozin, an inhibitor of sodium-glucose co-transporter 2, advances in the treatment of type 2 diabetes [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 569-588.
[5]	Aris Stiawan, Eti Nurwening Sholikhah, Yehezkiel Steven Kurniawan, Yoga Priastomo, Jumina. Synthesis, cytotoxicity assay, and molecular docking study of hydroxychalcone derivatives as potential tyrosinase inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 634-644.
[6]	Chunxing Li, Yuanmin Zhu, Hua Liu, Zhao Xu. Efficacy of prokinetic drugs in combination with proton pump inhibitors versus proton pump inhibitors alone in the treatment of gastroesophageal reflux disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(4): 347-356.
[7]	Jing Zhou, Hong Zhang, Xiaojiao Li, Xiangshi Song, Mengmeng Zhang, Yanhua Ding. Analysis of the effect of HCV resistance-associated substitutions on the short-term efficacy of DAA after single administration in three phase Ib clinical trials [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 133-145.
[8]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xiaoda Yang has made important progress in protein phosphatase inhibitors based on vanadium active groups [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(11): 932-933.
[9]	State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xinjing Tang has made progress in the study of cyclic antisense oligonucleotides as microRNA inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(10): 855-856.
[10]	Peili Jiao, Yiyan Li, Xing Wu, Yuxi Wang, Beibei Mao, Hongwei Jin, Lihe Zhang, Liangren Zhang, Zhenming Liu. Structure-based design and biological evaluation of novel mTOR inhibitors as potential anti-cervical agents [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 603-616.
[11]	Jiapei Yu, Yan Niu, Qi Sun, Fengrong Xu, Lei Liang, Chao Wang, Ping Xu. Design and synthesis of 2-aminobenzimidazoles as potential BACE1 inhibitors [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 650-659.
[12]	Huixia Yang, Ken Chen, Shuyao Liang, Suodi Zhai, Zhanmiao Yi. Effect of cytochrome P-450 inhibitors on pharmacokinetics and safety of voriconazole [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(3): 202-211.
[13]	Shuyang Yao, Yue Zhou. Study on the dipeptide vinyl sulfonamide derivatives as proteasome inhibitor [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(6): 408-418.
[14]	Yuanxin Li, Zifei Han, Chao Tian, Zhili Zhang, Junyi Liu. Design, synthesis and evaluation of novel non-ATP competitive CHK1 inhibitors as chemotherapy sensitizing agents [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(10): 726-736.
[15]	Ting Sun, Xia Yuan, Wei Huang, Wei Guo, Zemei Ge, Runtao Li, Jingrong Cui . Effects and mechanism of proteasome inhibitor YSY01-A alone or in combination with cisplatin against A549 cells in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(9): 607-616.